At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Post-Market Trading 05-16 17:12:58 EDT
3.22
-0.16
-4.73%
盘后3.27
+0.05+1.55%
17:11 EDT
High3.36
Low3.22
Vol232.65K
Open3.35
D1 Closing3.38
Amplitude4.14%
Mkt Cap71.54M
Tradable Cap57.23M
Total Shares22.22M
T/O765.11K
T/O Rate1.31%
Tradable Shares17.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.